2024 ARRS ANNUAL MEETING - ABSTRACTS

RETURN TO ABSTRACT LISTING


E5137. Breast Cancer by Molecular Subtypes: Imaging Features, Treatment, and Prognosis
Authors
  1. Daniel Montes; Department of Radiology, University of Colorado
  2. Jacob Fang; Department of Radiology, University of Colorado
  3. Hannah Chung; Department of Radiology, University of Colorado
Background
Breast cancer is the most common cancer in women worldwide and presents with a wide spectrum of appearances. Current research has identified four biomolecular subtypes based on gene expression and hormone receptor status: luminal A, luminal B, HER2-enriched, and basal-like cancers. Characterizing breast cancers by this approach provides prognostic information and is now the standard of care. Advances in radiomics have improved the ability to predict the biologic aggressiveness of a breast cancer based on imaging features, which in turn affects treatment and overall outcomes.

Educational Goals / Teaching Points
Describe the four molecular subtypes of breast cancer. Explore the key imaging differences based on the molecular phenotype. Discuss the treatment regimens, recurrence risk, and the overall prognosis for each molecular subtype.

Key Anatomic/Physiologic Issues and Imaging Findings/Techniques
This exhibit will present a pictorial essay of the key imaging features of breast cancer based on the molecular subtype. Mammographic, sonographic, MRI, and metabolic imaging features of luminal A, luminal B, HER2-enriched, and basal-like cancers will be illustrated. Additionally, this exhibit will investigate the role of precision medicine in determining treatment response, prognosis, and risk of recurrence based on breast cancer biomarkers.

Conclusion
Imaging characterization of breast cancer at the molecular level is an advance in precision medicine, which allows for effective treatment and counseling of patients.